Charles Schwab
KRON

Charles Schwab’s Kronos Bio KRON Stock Holding History

Charles Schwab’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,500
Closed -$20.6K – 3497
2023
Q4 		$20.6K Hold
16,500
– – ﹤0.01% 3481
2023
Q3 		$21.4K Sell
16,500
-227,216
-93% -$367K ﹤0.01% 3508
2023
Q2 		$419K Sell
243,716
-72,215
-23% -$115K ﹤0.01% 3138
2023
Q1 		$461K Buy
315,931
+26,416
+9% +$50.6K ﹤0.01% 2976
2022
Q4 		$469K Sell
289,515
-27,262
-9% -$62.7K ﹤0.01% 3018
2022
Q3 		$1.06M Buy
316,777
+33,810
+12% +$153K ﹤0.01% 2777
2022
Q2 		$1.03M Buy
282,967
+10,712
+4% +$48.6K ﹤0.01% 2784
2022
Q1 		$1.97M Sell
272,255
-13,903
-5% -$119K ﹤0.01% 2653
2021
Q4 		$3.89M Buy
286,158
+5,573
+2% +$87.2K ﹤0.01% 2472
2021
Q3 		$5.88M Buy
280,585
+134,534
+92% +$2.89M ﹤0.01% 2299
2021
Q2 		$3.5M Buy
146,051
+50,690
+53% +$1.28M ﹤0.01% 2525
2021
Q1 		$2.79M Buy
95,361
+4,020
+4% +$118K ﹤0.01% 2555
2020
Q4 		$2.73M Buy
+91,341
New +$2.87M ﹤0.01% 2508

Other funds holding KRON

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Charles Schwab's KRON Position: Q1 2024 in Review

Charles Schwab sold out of Kronos Bio (KRON) in Q1 2024, closing a stake of 16,500 shares — an estimated $20.6K sold.

Charles Schwab first reported a position in KRON in Q4 2020 and held it in 13 quarters. The position peaked at $5.88M in Q3 2021. 58 funds tracked by Wall St. Rank hold KRON as of Q1 2024.

  • Charles Schwab reported no remaining Kronos Bio position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 16,500 Kronos Bio shares in Q1 2024, an estimated $20.6K.
  • Charles Schwab first reported a position in Kronos Bio in Q4 2020 and held it in 13 quarters.
  • Charles Schwab's Kronos Bio position peaked at $5.88M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.